Document is current
Any future updates will be listed below
-
Authors
Ishowo-Adejumo, Rahmat
Zareba, Agnieszka
Wajsbrot, Dalia
Wolk, Robert
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04006457 at ClinicalTrials.govDocuments that mention this clinical trial
Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
https://doi.org/10.1007/s13555-025-01648-z
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
https://doi.org/10.1007/s40257-026-01029-y
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
https://doi.org/10.1007/s40257-024-00846-3
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 28 October 2025
Accepted: 23 December 2025
First Online: 24 January 2026
Declarations
:
: Rahmat Ishowo-Adejumo, Agnieszka Zareba, Dalia Wajsbrot, and Robert Wolk are employees of and may hold stock or stock options in Pfizer Inc.
: This sub-study was conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by each center’s institutional review board or ethics committee. All patients provided written informed consent.
